PRME 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
PRME 近期報酬表現
3.74%
Prime medicine inc
1.05%
同產業平均
0.48%
S&P500
與 PRME 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
CRL | Charles river laboratories international inc | 5 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
PAHC | Phibro animal health corp | 3 分 | 5 分 | 4 分 | 2 分 | 5 分 | |
AURA | Aura biosciences inc | - | 2 分 | 4 分 | 3 分 | 1 分 | |
ABCL | Abcellera biologics inc | 4 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
NRIX | Nurix therapeutics inc | 4 分 | 5 分 | 3 分 | 3 分 | 1 分 |
- CRL Charles river laboratories international inc價值 5 分趨勢 2 分波段 2 分籌碼 3 分股利 1 分查看更多
PRME 公司資訊
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.